{"id":26816,"date":"2024-11-05T04:00:00","date_gmt":"2024-11-04T20:00:00","guid":{"rendered":"http:\/\/csccm.org.cn\/?p=26816"},"modified":"2024-11-05T05:47:08","modified_gmt":"2024-11-04T21:47:08","slug":"lancet%e5%8f%91%e8%a1%a8%e8%ae%ba%e6%96%87%ef%bc%9a%e5%bf%83%e8%82%8c%e6%a2%97%e5%a1%9e%e7%9b%b8%e5%85%b3%e5%bf%83%e6%ba%90%e6%80%a7%e4%bc%91%e5%85%8b%e7%9a%84%e4%b8%b4%e6%97%b6%e6%9c%ba%e6%a2%b0","status":"publish","type":"post","link":"https:\/\/csccm.org.cn\/?p=26816","title":{"rendered":"[Lancet\u53d1\u8868\u8bba\u6587]\uff1a\u5fc3\u808c\u6897\u585e\u76f8\u5173\u5fc3\u6e90\u6027\u4f11\u514b\u7684\u4e34\u65f6\u673a\u68b0\u5faa\u73af\u652f\u6301"},"content":{"rendered":"\n<p><strong>ARTICLES<\/strong><a href=\"https:\/\/www.thelancet.com\/journals\/lancet\/issue\/vol404no10457\/PIIS0140-6736(24)X0037-9\"> <\/a><a href=\"https:\/\/www.thelancet.com\/journals\/lancet\/issue\/vol404no10457\/PIIS0140-6736(24)X0037-9\">Volume 404,\u00a0Issue 10457<\/a> P1019-1028 September 14, 2024<\/p>\n\n\n\n<h1 class=\"wp-block-heading\">Temporary mechanical circulatory support in infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials with 6-month follow-up<\/h1>\n\n\n\n<h3 class=\"wp-block-heading\">Holger\u00a0Thiele,\u00a0Jacob E\u00a0M\u00f8ller,\u00a0Jose P S\u00a0Henriques,\u00a0et al<\/h3>\n\n\n\n<h3 class=\"wp-block-heading\">Lancet 2024: 404: 1019 - 1028<\/h3>\n\n\n\n<h2 class=\"wp-block-heading\">Summary<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Background<\/h3>\n\n\n\n<p>Percutaneous active mechanical circulatory support (MCS) devices are being increasingly used in the treatment of acute myocardial infarction-related cardiogenic shock (AMICS) despite conflicting evidence regarding their effect on mortality. We aimed to ascertain the effect of early routine active percutaneous MCS versus control treatment on 6-month all-cause mortality in patients with AMICS.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Methods<\/h3>\n\n\n\n<p>In this individual patient data meta-analysis, randomised controlled trials of potential interest were identified, without language restriction, by querying the electronic databases MEDLINE via PubMed, Cochrane Central Register of Controlled Trials, and Embase, as well as&nbsp;<a href=\"http:\/\/clinicaltrials.gov\/\" target=\"_blank\" rel=\"noreferrer noopener\">ClinicalTrials.gov<\/a>, up to Jan 26, 2024. All randomised trials with 6-month mortality data comparing early routine active MCS (directly in the catheterisation laboratory after randomisation) versus control in patients with AMICS were included. The primary outcome was 6-month all-cause mortality in patients with AMICS treated with early routine active percutaneous MCS versus control, with a focus on device type (loading, such as venoarterial extracorporeal membrane oxygenation [VA-ECMO]&nbsp;<em>vs<\/em>&nbsp;unloading) and patient selection. Hazard ratios (HRs) of the primary outcome measure were calculated using Cox regression models. This study is registered with PROSPERO, CRD42024504295.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Findings<\/h3>\n\n\n\n<p>Nine reports of randomised controlled trials (n=1114 patients) were evaluated in detail. Overall, four randomised controlled trials (n=611 patients) compared VA-ECMO with a control treatment and five randomised controlled trials (n=503 patients) compared left ventricular unloading devices with a control treatment. Two randomised controlled trials also included patients who did not have AMICS, who were excluded (55 patients [44 who were treated with VA-ECMO and 11 who were treated with a left ventricular unloading device]). The median patient age was 65 years (IQR 57\u201373); 845 (79\u00b79%) of 1058 patients with data were male and 213 (20\u00b71%) were female. No significant benefit of early unselected MCS use on 6-month mortality was noted (HR 0\u00b787 [95% CI 0\u00b774\u20131\u00b703]; p=0\u00b710). No significant differences were observed for left ventricular unloading devices versus control (0\u00b780 [0\u00b762\u20131\u00b702]; p=0\u00b7075), and loading devices also had no effect on mortality (0\u00b793 [0\u00b775\u20131\u00b717]; p=0\u00b755). Patients with ST-elevation cardiogenic shock without risk of hypoxic brain injury had a reduction in mortality with MCS use (0\u00b777 [0\u00b761\u20130\u00b797]; p=0\u00b7024). Major bleeding (odds ratio 2\u00b764 [95% CI 1\u00b791\u20133\u00b765]) and vascular complications (4\u00b743 [2\u00b737\u20138\u00b726]) were more frequent with MCS use than with control.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/ars.els-cdn.com\/content\/image\/1-s2.0-S014067362401448X-gr1_lrg.jpg\" alt=\"\"\/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/ars.els-cdn.com\/content\/image\/1-s2.0-S014067362401448X-gr2_lrg.jpg\" alt=\"\"\/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/ars.els-cdn.com\/content\/image\/1-s2.0-S014067362401448X-gr3_lrg.jpg\" alt=\"\"\/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\">Interpretation<\/h3>\n\n\n\n<p>The use of active MCS devices in patients with AMICS did not reduce 6-month mortality (regardless of the device used) and increased major bleeding and vascular complications. However, patients with ST-elevation cardiogenic shock without risk of hypoxic brain injury had a reduction in mortality after MCS use. Therefore, the use of MCS should be restricted to certain patients only.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Funding<\/h3>\n\n\n\n<p>The Heart Center Leipzig at Leipzig University and the Foundation Institut f\u00fcr Herzinfarktforschung.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ARTICLES Volume 404,\u00a0Issue 10457 P1019-1028 September 1 [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[32,23],"tags":[],"_links":{"self":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/26816"}],"collection":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=26816"}],"version-history":[{"count":1,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/26816\/revisions"}],"predecessor-version":[{"id":26817,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/26816\/revisions\/26817"}],"wp:attachment":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=26816"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=26816"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=26816"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}